Phaseline

Companies › Onconic Therapeutics

Onconic Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Gastroenterology, Other, Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JP-1366
unclear - likely proton pump inhibitor or gastric protection agent
–Phase 3Peptic Ulcer; Drug Drug Interaction (DDI)Aug 2027
JPI-547–Phase 1Pancreatic Ductal AdenocarcinomaApr 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07265466JP-1366Phase 1Drug Drug Interaction (DDI)OtherMar 2026
NCT06439563JP-1366Phase 3Peptic UlcerGastroenterologyAug 2027
NCT05257993JPI-547Phase 1Pancreatic Ductal AdenocarcinomaOncologyApr 2030

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

J-Pharma SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany Lee's Pharmaceutical Zhejiang Doer Biologics InventisBio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.